Documentos relacionados

1. Clinical features and genetic characteristics of myoclonic-atonic epilepsy caused by SLC6A1 gene mutation
2. [Autosomal dominant mental retardation type 5 caused by <i>SYNGAP1</i> gene mutations: a report of 8 cases and literature review].
3. Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial.
4. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.
5. Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability.
6. A novel de novo TET3 loss-of-function variant in a Turkish boy presenting with neurodevelopmental delay and electrical status epilepticus during slow-wave sleep.
7. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.